Table 2.
Cell | Observed effects | References |
---|---|---|
Monocytes | Reduction of proinflammatory cytokines | [49, 50] |
Reduction of surface molecules | [52] | |
| ||
Macrophages | Reduction of proinflammatory cytokines | [56, 58–61, 66, 76] |
Reduction of costimulatory molecules | [61] | |
Reduction of ROS and NO | [57, 58, 63] | |
Reduction of phagocytosis of extracellular pathogens | [63] | |
Mycobacterium tuberculosis replication control | [64–67] | |
| ||
Dendritic cells | Reduction of proinflammatory cytokines | [59, 81, 82] |
Reduction of costimulatory molecules | [59, 79–82] | |
Reduction of MHC-II | [82] | |
| ||
Neutrophils | Reduction of phagocytosis | [90] |
Reduction of chemotaxis | [90] | |
Cellular arrest | [84] | |
Apoptosis | [68] | |
| ||
Eosinophils | Eosinophilia in some clinical studies | [93–97] |
| ||
Basophils | Reduction in total numbers in mouse autoimmune lymphoproliferative syndrome models | [99] |
| ||
Mast cells | Reduction of cellular proliferation and viability | [100] |
| ||
NK lymphocytes | Reduction of cellular proliferation | [109] |
Reduction of cytotoxic activity | [101–106] | |
| ||
Tγδ lymphocytes | Apoptosis | [110, 111] |
| ||
B cells | Inhibition of differentiation of B cell into plasma cell | [112–115] |
| ||
T CD4+ lymphocytes | Reduction of cellular viability | [120, 129] |
Reduction in proinflammatory cytokines | [50, 124, 126, 128] | |
| ||
T CD8+ lymphocytes | Reduction of cytotoxic activity | [116] |
Reduction of cellular viability | [120] | |
| ||
Treg lymphocytes | Increase of cellular proliferation | [122, 124, 125, 127, 135, 136] |
Increase in FoxP3 expression | [126, 133, 134] | |
Increase of suppressor activity | [135–137] |
ROS: reactive oxygen species; NO: nitric oxide; MHC-II: major histocompatibility molecule II.